U.S. MARKETS FOR ARRHYTHMIA MANAGEMENT PRODUCTS

305 Pages | 78 Exhibits | 2005 Analysis | Forecasts Through 2017 Product Family: Market Reports




OVERVIEW:
Cardiac arrhythmias affect more than 5 million people nationwide, and result in more than 1.2 million hospitalizations and 400,000 deaths each year in the U.S. Arrhythmia management involves the use of a variety of products that enable clinicians to detect the presence of cardiac arrhythmias and determine their nature and extent, allowing the selection of appropriate treatment protocols, evaluation of chosen therapies, and establishment of patients' long-term prognoses.

Products utilized in arrhythmia management include anti-arrhythmic pharmaceuticals and devices such as arrhythmia ablation products, cardiac resynchronization therapy (CRT) systems, electrocardiography (ECG) systems, electrophysiology (EP) catheters, external defibrillators, implantable cardioverter defibrillators (ICDs), and pacemakers. The U.S. market for these products, which was valued at $8.1 billion in 2003, is projected to grow at a compound annual rate of 9.7% during the forecast period covered by this report, reaching an estimated value of $20.5 billion in the year 2013.

This dynamic report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. market for arrhythmia management products.

Covered topics in this report include advanced and conventional ablation catheters; anticoagulants; automated external defibrillators; cardiac arrhythmia statistics; Class I, Class II, Class III, and Class IV anti-arrhythmic drugs; CRT systems; diagnostic EP catheters; dual-channel pacemakers; ECG systems; ICD systems; manual external defibrillators; procedure volumes forecasts; semi-automatic external defibrillators; single-channel pacemakers; and surgical ablation probes.

TABLE OF CONTENTS:

EXECUTIVE SUMMARY

i.   Arrhythmia Management Devices Market

a. Electrocardiography Systems

b. Pacemakers

c. Cardiac Resynchronization Systems

d. Implantable Cardioverter Defibrillators

e. External Defibrillators

f. Electrophysiology and Ablation Catheters

 i.  Diagnostic Electrophysiology Catheters

 ii. Ablation Catheters

g. Surgical Ablation Systems

ii.  Arrhythmia Management Pharmaceuticals Market

a. Class I Anti-Arrhythmic Drugs

b. Class II Anti-Arrhythmic Drugs

c. Class III Anti-Arrhythmic Drugs

d. Class IV Anti-Arrhythmic Drugs

e. Anticoagulants

iii.  Report Methodology

 

1. CLINICAL OVERVIEW OF ARRHYTHMIA DISORDERS

1.1 Anatomy and Physiology of the Heart

1.2 The Cardiac Conduction System

1.3 Cardiac Arrhythmias

1.3.1 Sinus Bradycardia

1.3.2 Sick Sinus Syndrome

1.3.3 Heart Block

1.3.3.1 Atrioventricular Block

1.3.3.2 Infranodal Atrioventricular Block

1.3.3.3 Intraventricular Block

1.3.3.4 Sinoatrial Block

1.3.4 Supraventricular Tachycardia

1.3.4.1 Atrial Fibrillation

1.3.4.2 Atrial Flutter

1.3.4.3 His Bundle Rhythm Disorders

1.3.5 Ventricular Tachycardia

1.3.6 Ventricular Fibrillation

1.4 Congestive Heart Failure

1.5 Sudden Cardiac Death

 

2. CLINICAL MANAGEMENT OF ARRHYTHMIA DISORDERS

2.1 Changing Demographics

2.2 Cardiac Arrhythmia Diagnosis

2.2.1 Electrocardiography-Based Diagnostic Procedures

2.2.1.1 Resting Electrocardiography

2.2.1.2 Holter Monitoring

2.2.1.3 Trans-Telephonic Event Recording

2.2.1.4 Signal-Averaging Electrocardiography

2.2.1.5 Exercise Stress Testing

2.2.2 Echocardiography

2.2.3 Tilt-Table Testing

2.2.4 Electrophysiology Studies

2.2.4.1 Conventional versus Advanced Mapping/Navigation Systems

2.2.4.2 Procedure Volumes Forecast

2.3 Cardiac Arrhythmia Treatment

2.3.1 Anti-Arrhythmic Pharmaceuticals

2.3.2 Cardiac Pacing

2.3.2.1 Device Technology

2.3.2.2 Fixed-Rate and Demand Devices

2.3.2.3 Single-Chamber and Dual-Chamber Devices

2.3.2.4 Rate-Responsive Devices

2.3.2.5 Leads and Electrodes

2.3.2.6 Indications for Pacemaker Implantation

2.3.2.7 Pacemaker Selection and Programming

2.3.2.8 Temporary Pacing Systems

2.3.2.9 Placement Forecast

2.3.3 Cardiac Resynchronization Therapy

2.3.3.1 Clinical Study Results

2.3.3.2 Placement Forecast

2.3.4 Implantable Cardioverter Defibrillation

2.3.4.1 Clinical Study Results

2.3.4.2 Device Technology

2.3.4.3 Product Selection

2.3.4.4 Device Implantation

2.3.4.5 Placement Forecast

2.3.5 External Defibrillation

2.3.5.1 Technology

2.3.5.2 Public Access Defibrillation Trial

2.3.5.3 Procedure Volumes Forecast

2.3.6 Arrhythmia Ablation

2.3.6.1 Transcatheter Radiofrequency Ablation Techniques

2.3.6.1.1 Conventional Radiofrequency Ablation

2.3.6.1.2 Advanced Radiofrequency Ablation

2.3.6.2 Cryoablation Techniques

2.3.6.3 Surgical Arrhythmia Ablation Techniques

2.3.6.3.1 Radiofrequency

2.3.6.3.2 Microwave

2.3.6.3.3 Ultrasound

2.3.6.3.4 Argon-Based

2.3.6.3.5 Laser

2.3.6.4 Procedure Volumes Forecast

 

3. ARRHYTHMIA MANAGEMENT DEVICES MARKET

3.1 Electrocardiography Systems

3.1.1 Products

3.1.2 Market Forecast

3.1.3 Competitive Analysis

3.2 Pacemakers

3.2.1 Products

3.2.2 Market Forecast

3.2.3 Competitive Analysis

3.3 Cardiac Resynchronization Systems

3.3.1 Products

3.3.2 Market Forecast

3.3.3 Competitive Analysis

3.4 Implantable Cardioverter Defibrillators

3.4.1 Products

3.4.2 Market Forecast

3.4.3 Competitive Analysis

3.5 External Defibrillators

3.5.1 Products

3.5.2 Market Forecast

3.5.3 Competitive Analysis

3.6 Electrophysiology and Ablation Catheters

3.6.1 Diagnostic Electrophysiology Catheters

3.6.1.1 Market Forecast

3.6.1.2 Competitive Analysis

3.6.2 Ablation Catheters

3.6.2.1 Market Forecast

3.6.2.2 Competitive Analysis

3.7 Surgical Ablation Systems

3.7.1 Products

3.7.2 Market Forecast

3.7.3 Competitive Analysis

 

4. ARRHYTHMIA MANAGEMENT PHARMACEUTICALS MARKET

4.1 Proarrhythmia

4.2 Classification of Anti-Arrhythmic Drugs

4.3 Anti-Arrhythmic Drugs, by Primary Mechanism

4.3.1 Class I

4.3.1.1 Class IA

4.3.1.2 Class IB

4.3.1.3 Class IC

4.3.2 Class II

4.3.3 Class III

4.3.4 Class IV

4.3.5 Other Drugs Used to Control Arrhythmias

4.4 Adverse Effects and Monitoring of Anti-Arrhythmic Drugs

4.5 Rate Control versus Rhythm Control

4.6 Cardioversion

4.7 Anti-Arrhythmic Drugs in Development

4.8 Anticoagulants

4.9 Generics

4.10 Class I Anti-Arrhythmic Drugs, Market Forecast

4.10.1 Competitive Analysis

4.11 Class II Anti-Arrhythmic Drugs, Market Forecast

4.11.1 Competitive Analysis

4.12 Class III Anti-Arrhythmic Drugs, Market Forecast

4.12.1 Competitive Analysis

4.13 Class IV Anti-Arrhythmic Drugs, Market Forecast

4.13.1 Competitive Analysis

4.14 Warfarin and Other Anticoagulants, Market Forecast

4.14.1 Competitive Analysis

4.15 Anti-Arrhythmic Drugs and Anticoagulants, Combined Market Forecast

 

5. COMPANY PROFILES

5.1   AtriCure, Inc

5.2   C.R. Bard, Inc.

5.3   Berlex, Inc./Schering AG

5.4   Biosense Webster, Inc./Johnson & Johnson

5.5   Biotronik GmbH & Company KG

5.6   Boston Scientific Corporation

5.7   Bristol-Myers Squibb Company

5.8   ELA Medical, Inc./Sorin Group

5.9   Endocardial Solutions, Inc.

5.10 GE Healthcare, Inc./General Electric Company

5.11 Guidant Corporation

5.12 Medtronic, Inc.

5.13 Philips Medical Systems North America/Royal Philips Electronics NV

5.14 Reliant Pharmaceuticals LLC

5.15 St. Jude Medical, Inc.

5.16 Upsher-Smith Laboratories, Inc.

5.17 ZOLL Medical Corporation

 

APPENDIX:  COMPANY LISTING

 

LIST OF EXHIBITS

 

Exhibit ES-1:    Incidence and Prevalence Statistics for Selected Cardiac Arrhythmias and Other Conditions, 2001 and 2013

Exhibit ES-2:    United States, Selected Population Statistics, 2003 and 2013

Exhibit ES-3:    Arrhythmia Management Products, Market Forecast, 2003-2013

Exhibit ES-4:    Arrhythmia Management Devices, Market Forecast, 2003-2013

Exhibit ES-5:    Electrocardiography Products, Market Forecast, 2003-2017

Exhibit ES-6:    Single- and Dual-Chamber Pacemakers, Market Forecast, 2003-2013

Exhibit ES-7:    Cardiac Resynchronization Systems, Market Forecast, 2003-2013

Exhibit ES-8:    Implantable Cardioverter Defibrillator Systems, Market Forecast, 2003-2013

Exhibit ES-9:    External Defibrillator Systems, Market Forecast, 2003-2013

Exhibit ES-10:   Diagnostic Electrophysiology Catheters, Market Forecast, 2003-2013

Exhibit ES-11:   Ablation Catheters, Market Forecast, 2003-2013

Exhibit ES-12:   Surgical Ablation Probes, Market Forecast, 2003-2013

Exhibit ES-13:   Anti-Arrhythmic Drugs and Anticoagulants, Combined Market Forecast

 

Exhibit 1-1:      Incidence and Prevalence Statistics for Selected Cardiac Arrhythmias and Other Conditions, 2001 and 2013

Exhibit 1-2:      2001, Total Mention Mortality Figures for Selected Cardiac Arrhythmias

 

Exhibit 2-1:      United States, Selected Population Statistics, 2003 and 2013

Exhibit 2-2:      Diagnostic Electrocardiography, Procedure Volumes Forecast, 2003-2013

Exhibit 2-3:      Electrophysiology Diagnostics, Procedure Volumes Forecast, 2003-2013

Exhibit 2-4:      Selected Arrhythmia Disorders and Available Treatment Protocols

Exhibit 2-5:      Vaughn Williams Classification of Anti-Arrhythmic Pharmaceuticals, by Action Mechanism

Exhibit 2-6:      The NASPE/BPEG Generic Code for Pacing

Exhibit 2-7:      Pacemaker Rate-Adaptive Technologies

Exhibit 2-8:      Comparison of Selected Rate-Adaptive Pacing Methods

Exhibit 2-9:      Selected Rate-Adaptive Pacing Modalities

Exhibit 2-10:     Pacemakers, Placement Forecast, 2003-2013

Exhibit 2-11:     Cardiac Resynchronization Therapy Systems, Placement Forecast, 2003-2013

Exhibit 2-12:     The NASPE/BPEG Defibrillator Code

Exhibit 2-13:     NASPE/BPEG Defibrillator Coding for Selected Types of Implantable Cardioverter Defibrillators

Exhibit 2-14:     Implantable Cardioverter Defibrillators, Placement Forecast, 2003-2013

Exhibit 2-15:     Emergency Defibrillation, Procedure Volumes Forecast, 2003-2013

Exhibit 2-16:     Arrhythmia Ablation, Procedure Volumes Forecast, 2003-2013

 

Exhibit 3-1:      Arrhythmia Management Devices, Market Forecast, 2003-2013

Exhibit 3-2:      2004, Selected Electrocardiography Systems

Exhibit 3-3:      Electrocardiography Products, Market Forecast, 2003-2017

Exhibit 3-4:      2003, Electrocardiography Products Market, Share by Supplier

Exhibit 3-5:      2004, Selected Pacemaker Systems

Exhibit 3-6:      Single- and Dual-Chamber Pacemakers, Market Forecast, 2003-2013

Exhibit 3-7:      Dual-Chamber Pacemaker Systems, Market Forecast, 2003-2013

Exhibit 3-8:      Single-Chamber Pacemaker Systems, Market Forecast, 2003-2013

Exhibit 3-9:      2003, Pacemakers Market, Share by Supplier

Exhibit 3-10:     2004, Selected Cardiac Resynchronization Therapy Systems

Exhibit 3-11:     Cardiac Resynchronization Systems, Market Forecast, 2003-2013

Exhibit 3-12:     2004, Selected Implantable Cardioverter Defibrillator Systems

Exhibit 3-13:     Implantable Cardioverter Defibrillator Systems, Market Forecast, 2003-2013

Exhibit 3-14:     2003, Implantable Cardioverter Defibrillators Market, Share by Supplier

Exhibit 3-15:     2004, Selected External Defibrillator Systems

Exhibit 3-16:     External Defibrillator Systems, Market Forecast, 2003-2013

Exhibit 3-17:     First-Responder/Public Access Automated External Defibrillator Systems, Market Forecast, 2003-2013

Exhibit 3-18:     Manual External Defibrillator Systems, Market Forecast, 2003-2013

Exhibit 3-19:     Semi-Automatic External Defibrillator Systems, Market Forecast, 2003-2013

Exhibit 3-20:     2003, External Defibrillator Systems Market, Share by Supplier

Exhibit 3-21:     2004, Selected Diagnostic Electrophysiology Catheters

Exhibit 3-22:     Diagnostic Electrophysiology Catheters, Market Forecast, 2003-2013

Exhibit 3-23:     Conventional Diagnostic Electrophysiology Catheters, Market Forecast, 2003-2013

Exhibit 3-24:     Advanced Diagnostic/Mapping Electrophysiology Catheters, Market Forecast, 2003-2013

Exhibit 3-25:     2003, Conventional Diagnostic Electrophysiology Catheters Market, Share by Supplier

Exhibit 3-26:     2003, Advanced Diagnostic/Mapping Electrophysiology Catheters Market, Share by Supplier

Exhibit 3-27:     2004, Selected Ablation Catheters

Exhibit 3-28:     Ablation Catheters, Market Forecast, 2003-2013

Exhibit 3-29:     Conventional Ablation Catheters, Market Forecast, 2003-2013

Exhibit 3-30:     Advanced Ablation Catheters, Market Forecast, 2003-2013

Exhibit 3-31:     2003, Conventional Ablation Catheters Market, Share by Supplier

Exhibit 3-32:     2003, Advanced Ablation Catheters Market, Share by Supplier

Exhibit 3-33:     2004, Selected Surgical Ablation Systems

Exhibit 3-34:     Surgical Ablation Probes, Market Forecast, 2003-2013

Exhibit 3-35:     2003, Surgical Ablation Probes Market, Share by Supplier

 

Exhibit 4-1:      Types of Proarrhythmia That May Stem from Anti-Arrhythmic Drug Treatment for Atrial Fibrillation and Atrial Flutter, by Vaughan Williams Classification

Exhibit 4-2:      2004, Selected Anti-Arrhythmic Drugs, by Vaughan Williams Classification

Exhibit 4-3:      Selected Anti-Arrhythmic Drugs and Possible Adverse Effects

Exhibit 4-4:      Class I Anti-Arrhythmic Drugs, Market Forecast, 2003-2013

Exhibit 4-5:      2003, Class I Anti-Arrhythmic Drugs Market, Share by Supplier

Exhibit 4-6:      Class II Anti-Arrhythmic Drugs, Market Forecast, 2003-2013

Exhibit 4-7:      2003, Class II Anti-Arrhythmic Drugs Market, Share by Supplier

Exhibit 4-8:      Class III Anti-Arrhythmic Drugs, Market Forecast, 2003-2013

Exhibit 4-9:      2003, Class III Anti-Arrhythmic Drugs Market, Share by Supplier

Exhibit 4-10:     Class IV Anti-Arrhythmic Drugs, Market Forecast, 2003-2013

Exhibit 4-11:     2003, Class IV Anti-Arrhythmic Drugs Market, Share by Supplier

Exhibit 4-12:     Warfarin and Other Anticoagulants for the Treatment of Cardiac Arrhythmias, Market Forecast, 2003-2013

Exhibit 4-13:     2003, Warfarin and Other Anticoagulants for the Treatment of Cardiac Arrhythmias Market, Share by Supplier

Exhibit 4-14:     Anti-Arrhythmic Drugs and Anticoagulants, Combined Market Forecast



Contact Us

Need help finding medtech research? Let us help you!